Moderna's stock surged 5% to $181.51, marking a 516% gain in 2026, driven by anticipation of late-October Phase 3 data for its personalized cancer therapy, intismeran autogene, developed with Merck. The therapy targets high-risk melanoma patients and showed promising early results in recurrence-free and distant metastasis-free survival. The upcoming data presentation at the European Society for Medical Oncology Congress could confirm the therapy's effectiveness or cause a sharp stock correction. Investors are advised to watch the detailed survival benefit data and approach Moderna stock cautiously due to the binary risk tied to this single event.
Moderna's stock price on Pluang is currently USD 183.81, up 6.29% as of September 22, 2026, 22:01 WIB, slightly higher than the article's noted 5% gain. The market cap of Moderna stands at $61.50 billion, reflecting strong investor interest. Meanwhile, Merck shares are trading at USD 151.82 with a 1.55% increase, showing moderate positive momentum alongside Moderna's surge.
